Evonik Nutrition & Care - Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €14.1 billion and earnings (adjusted EBITDA) of €1.9 billion in 2025. The common motivation of the approximately 31,000 employees: to provide customer
Exagen Inc. - Exagen Inc. is a patient-focused and discovery-driven commercial-stage life sciences company that is a global leader in autoimmune disease testing.
Harvard Bioscience - Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO. Headquartered in Holliston, Massachusetts, United States, the company's brands include: Biochrom, BTX, CMA, Data Sciences International (DSI), Harvard Apparatus, HEKA, Hugo Sachs Elektronik, KD Scientific, Multi Channel Systems (MCS), Panlab, and Warner Instruments.
Inte:Ligand - The Most User Friendly Molecular Design Platform: LigandScout LigandScout, the most user friendly molecular design software suite, seamlessly integrates our advanced pharmacophore and VS technologies with molecular docking tools to create an inspiring and productive experience for multidisciplinary teams. By providing excellent prediction quality with unprecedented speed, LigandScout successfully addresses challenges in interactive molecular design. [More info ...
Molecular Discovery - Molecular Discovery are experts in applying GRID Molecular Interaction Fields to Drug Discovery problems, as well as using chemometric or statistical methods to relate chemical structure to biological property.
Pii - Pii is a life sciences company headquartered in Mechelen, Belgium, founded in 2001.
SimBioSys - Our visualization and diagnostic technology is designed to deliver precision answers to critical clinical questions, enabling clinicians to individualize patient treatment. The heterogeneous nature of tumors can lead to diverse responses to treatment across patients and regions of the same tumor. Our comprehensive approach addresses tumor heterogeneity by looking at the tumor in its entirety - beyond biopsies or 2D pathology slides.